Teresa Harris Graham: Recognizing the Female Scientists Driving Breast Cancer Innovation
Teresa Harris Graham/LinkedIn

Teresa Harris Graham: Recognizing the Female Scientists Driving Breast Cancer Innovation

Teresa Harris Graham, CEO of Roche Pharmaceuticals, shared on LinkedIn:

“When a molecule becomes a medicine – that’s a milestone worth celebrating.

Now consider the fact that the people behind the molecule – those who designed, discovered and developed it into a medicine that has the potential to change the way the most common form of breast cancer is treated – were led by a group of female scientists.

Teresa Harris Graham

To anyone with a daughter or niece, a student or a friend interested in STEM, tell them that breakthroughs don’t happen by themselves; they take brilliant minds from all backgrounds coming together with a shared purpose.

At Roche and Genentech, we’ve been advancing breast cancer research for more than 30 years – but today somehow feels a little extra special.

Congrats Maura Dickler, Gina Xiaojing Wang, Ciara Metcalfe, Sandra Milan, Jennifer Leuchle, Lori Friedman and the many, many more who made this moment possible.”

FDA Approves Giredestrant Plus Everolimus

The FDA has approved giredestrant plus everolimus for adults with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation detected by an FDA-authorized test. Roche and Genentech announced the decision.

The approval covers two routes to eligibility based on when the disease returned or progressed. It includes patients whose breast cancer recurred during or after completion of endocrine-based adjuvant therapy, as well as patients whose disease progressed on at least one endocrine-based regimen in the metastatic setting.

In both cases, the ESR1 test result determines whether the tumor meets the biomarker requirement for the all-oral combination.

Learn more: FDA Approves Giredestrant Plus Everolimus for Advanced Breast Cancer With ER-Positive ESR1 Mutations

Teresa Harris Graham